tbuckley/cabot-search huggingface dataset:
POS1579-PARE LET’S TAKE AN HEALTHY WALK IN THE PARK
Authors: U. Viora, P. Guiso, M. T. Mascarino, G. Mascarino
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with RMDs are not yet used to live phisical activity such as an important part of their therapy; Covid 19 pandemic, with the restrictions imposed on interpersonal approaches and the the fear of being infected and spreading the virus, has further slowed down the way towards these kind of empowerment. During the pandemic, in Italy the number of pets (mainly dogs) had an exponencial increase. Animal Assisted Interventions /Animal Assisted Therapies seems to be really successful. Objectives Our project aims: to offer people with RMDs the opportunity to move playing fitwalking under control of WALKin trainers who can teach them the right way to practice this new discipline or simply walking properly with their dogs or playng rehabilitative exercises (specific for each one) with the help of animals specially trained. a number of meetings (at least 12) in which experts will discuss about RMDs, comorbidities, nature, animals, man-animal relationship adn so on. Methods Thanks to an agreement with a natural park (UNESCO MAB Collina Po reserve), we could draw 4 different routes (3-4-5-7 Km) and a safe area in which all the participants can play different activities. Based on the medical prescription, people will be assigned to different groups (no more than 7 people in each group) and to different activities (walking, rehabilitative exercises, alone or with animals). Twice a week during an hour the groups will meet and practice their activity, not only working together, but also sharing experiences, sesations, feeling. Each group will be lead by an expert (walking trainers, health pofessionals, teamsters). Either each group leader or each participant will wright a diary at the end of the activity session, to let us have a number of encoded informations which drive us to verify all progresses in term of improvement of mobility and mood and reduction of drugs cosumption. Results The participation (face to face and virtual) in the first three meetings (October, November 2021 and January 2022 has been continuously increasing and we have a good core of “fans”, but also every time a lot of new people who want to join us. We are collecting the first inscriptions and we preview to start the activity on March 20 when the first goups will be leaded by Maurizio Damilano, twice world and Olympic running champion and inventor of fitwalking. First preliminary results will be available in December 2022. Conclusion With this project we hope to help people with RMDs to live physical activity as an important part of their therapeutic pathway and to rediscover how nice it is to be together, finding new friends (either humans or animals) Disclosure of Interests None declared
POS0629 PREVALENCE AND FACTORS ASSOCIATED WITH SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: D. Bertelle, R. Bixio, E. Bertoldo, A. Giollo, S. Framarin, F. Pollastri, G. Orsolini, O. Viapiana, M. Rossini, G. Adami
Journal: Annals of the Rheumatic Diseases (2022)

Background Sarcopenia is a progressive and generalized skeletal muscle loss associated with falls, fractures, physical disability, and mortality, described as age-related or secondary. Systemic inflammatory diseases, such as rheumatoid arthritis (RA), are well-known causes of secondary sarcopenia. However, the exact prevalence of sarcopenia in patients with RA is still unknown, partly due to the heterogeneous definitions of sarcopenia adopted in different studies. Objectives To assess the prevalence of sarcopenia in a cohort of patients affected by RA, and to evaluate the influence of age, sex, comorbidity, disease duration and activity, antibody status and therapies on sarcopenia. Methods We conducted a retrospective observational study on adult patients affected by RA undergoing evaluation at our outpatient clinic from January 2009 and July 2021. All patients underwent dual-energy X-ray absorptiometry (DXA) for assessment of body composition; diagnosis of sarcopenia was defined using Skeletal Muscle Mass Index (SMI), as proposed by consensus EWGSOP2 (1). We collected relevant demographic, clinical, therapeutic, and laboratory data at the time of DXA. We excluded patients affected by neoplastic disorders and/or malnutrition. Binary logistic regression analysis was employed to define predictors and protective factors of developing sarcopenia. Results A total of 266 patients (82.7% women) with a median age of 58.4 (IQR 14.4) years were included in the study. The prevalence of sarcopenia was 27.44%. From the binary logistic regression analysis, we found that the use of oral glucocorticoids (GCs) at a daily dose &gt; 3.25 mg of prednisone-equivalent was significantly associated with sarcopenia (β 0.68, p = 0.047, aOR 1.98, 95% CI 1.009 – 3.881) (Figure 1). We found a significant inverse correlation between conventional disease-modifying antirheumatic drug (c-DMARDs) and sarcopenia (β -0.71, p = 0.027) as well. Age, sex, disease duration, mean disease activity - expressed as disease activity score based on 28 joints (DAS-28), erosive and seropositive disease - and biologic disease-modifying antirheumatic drug (b-DMARDs) therapy were not predictors of sarcopenia, albeit seropositive status showed a correlation trend with increased prevalence of sarcopenia (p = 0.092). Figure 1. Conclusion Our study showed that sarcopenia is a common complication in RA. Glucocorticoid therapy was associated with an increased prevalence of sarcopenia, while c-DMARDs acted as protective factors, possibly decreasing chronic inflammation. No correlation was found with b-DMARDs, possibly due to association with longer and more aggressive rheumatic disease. References [1]Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31 Disclosure of Interests None declared
AB1534-HPR ASSESSMENT OF BACK PAIN IN NURSES WORKING IN HOSPITALS AND OUTPATIENT CLINICS
Authors: B. Nieradko-Iwanicka
Journal: Annals of the Rheumatic Diseases (2022)

Background Back pain in a common health problem in nurses affecting 70-78% of them [1,2,3]. The risk of back pain in nurses increases by 35% for each additional working hour per day [2]. Objectives The aim of the study was to find out if nurses working in hospital wards suffer more from back pain than their counterparts employed in the outpatient clinics. Methods An online survey was conducted with use of an questionnaire containing questions about body mass index (BMI), Revised Oswestry Low Back Pain Disability Scale (ROLBPDS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Numeric Rating Scale (NRS) for pain. Questions about seniority and working hours were included.It was uploaded and shared on the Google online survey platform. Participation was anonymous and voluntary. An invitation was mailed to the members of The Lublin Chamber of Nurses and Midwives. A total of 163 nurses (161women and 2 men) aged 21-70 years filled in the questionnaire in February and March 2021.Of the group 82 were nurses from hospitals (NHs) and 81 from outpatient clinics (NOCs). Results The mean BMI of participants was 26.4kg/m 2 . In NHs the mean BMI was 25kg/m 2 and in NOCs 27.8kg/m 2 .Seventy five percent of HNs looked after lying patients.Ninety nine percent of NHs and 75% of NOCs suffered from back pain. In the NH group 73% reported pain in lumbar, 13% in thoracic and 14% in cervical spine. In the NOC group 15% complained about neck pain and the rest about low back pain. The mean ROLBPDS rating was 15 which means moderate disability. In NOCs it was 13 and in HNs it was 17. The mean back pain NRS was 6. In NOCs it was 3 and in NHs it was 9 (p&lt;0.05). There was a positive correlation between shift length and back pain measured with the NRS. As many as 5 participants had diagnosed seronegative spondyloarthropathy. In those mean BASDAI was 5.6±1 which means active disease. Conclusion Nurses working in hospital wards experience significantly more back pain than their counterparts working in outpatient clinics. Long working hours increase the risk for the ailment. References [1]Ibrahim MI, Zubair IU, Yaacob NM, Ahmad MI, Shafei MN. Low Back Pain and Its Associated Factors among Nurses in Public Hospitals of Penang, Malaysia. Int J Environ Res Public Health. 2019 Nov 1;16(21):4254. doi: 10.3390/ijerph16214254. PMID: 31683911; PMCID: PMC6861894. [2]Shieh SH, Sung FC, Su CH, Tsai Y, Hsieh VC. Increased low back pain risk in nurses with high workload for patient care: A questionnaire survey. Taiwan J Obstet Gynecol. 2016 Aug;55(4):525-9. doi: 10.1016/j.tjog.2016.06.013. PMID: 27590376. [3]Wolska D. Wpływ występowania dolegliwości bólowych kręgosłupa na jakość życia pielęgniarek -doniesienia wstępne, Innowacje w Pielęgniarstwie i Naukach o Zdrowiu 2018, 2 (3), 39-54 The impact of back pain on the quality of life of nurses - introductory reports, Innovations in Nursing and Health Sciences 2018, 2 (3), 39-54 (in Polish). Disclosure of Interests None declared
Protein tyrosine phosphatase PTPN22 negatively modulates platelet function and thrombus formation
Authors: Xiamin Wang, Guangyu Wei, Yangyang Ding, Xiang Gui, Huan Tong, Xiaoqi Xu, Sixuan Zhang, Zengtian Sun, Wen Ju, Yue Li, Ruosi Yao, Qingyu Wu, Zhihao Lu, Chunling Fu, Zhenyu Li, Si Zhang, Elizabeth E. Gardiner, Robert K. Andrews, Hu Hu, Lingyu Zeng, Kailin Xu, Jianlin Qiao
Journal: Blood (2022)
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns
Authors: Ghina R Mumtaz, Hiam Chemaitelly, Sawsan AlMukdad, Aisha Osman, Sasha Fahme, Nesrine A Rizk, Shereen El Feki, Laith J Abu-Raddad
Journal: The Lancet HIV (2022)
Multiplexed Ultrasound Imaging Using Spectral Analysis on Gas Vesicles
Authors: Sangnam Kim, Siyuan Zhang, Sangpil Yoon
Journal: Advanced Healthcare Materials (2022)

Current advances in ultrasound imaging techniques combined with the next generation contrast agents such as gas vesicles (GV) revolutionize the visualization of biological tissues with spatiotemporal precision. In optics, fluorescent proteins enable understanding of molecular and cellular functions in biological systems due to their multiplexed imaging capability. Here, a panel of GVs is investigated using mid-band fit (MBF) spectral imaging to realize multiplexed ultrasound imaging to uniquely visualize locations of different types of stationary GVs. The MBF spectral imaging technique demonstrates that stationary clustered GVs are efficiently localized and distinguished from unclustered GVs in agarose gel phantom and 3D vessel structures are visualized in ex vivo mouse liver specimens. Mouse macrophages serve as carriers of clustered and unclustered GVs and multiplexing beacons to report cells' spatial locations by emitting distinct spectral signals. 2D MBF spectral images are reconstructed, and pixels in these images are classified depending on MBF values by comparing predetermined filters that predict the existence of cells with clustered and unclustered GVs. This pseudo-coloring scheme clearly distinguishes the locations of two classes of cells like pseudo-color images in fluorescence microscopy.
AB1271 PREVALENCE OF RHEUMATOLOGIC DISEASES IN PATIENTS PRESENTING WITH UVEITIS
Authors: E. Ozturk, T. Yuce Inel, M. Kaya, F. Onen, G. Can
Journal: Annals of the Rheumatic Diseases (2022)

Background Uveitis may occur in the course of systemic inflammatory rheumatic diseases, or it may be the first clinical presentation of these diseases. Objectives To determine the prevalence of systemic inflammatory rheumatic disease in patients whose initial clinical manifestation is non-infectious uveitis. Methods Adult patients diagnosed with non-infectious uveitis in Dokuz Eylul University Ophthalmology Department and referred to investigate the etiology of rheumatological disease were included in the study. Demographic and clinical features, laboratory and imaging findings of the patients were examined. Results 106 patients diagnosed with uveitis (42.4% anterior uveitis, 2.8% intermediate uveitis, 19.8% posterior uveitis, 34.9% panuveitis) were included in the study. 52.8% of the patients were male and the mean age was 40.19±14.82 years. The mean age of uveitis attack was 38.7±15.02 years. 33% of the patients were diagnosed with rheumatologic disease (10 SpA, 17 Behçet’s Disease, two vasculitis, two sarcoidosis, three undifferentiated connective tissue disease, one rheumatoid arthritis). SpA was diagnosed in 20% of patients presenting with anterior uveitis. Behçet’s disease was detected in 27% of patients referred with panuveitis and in 33.3% of patients whose first clinical finding was posterior chamber involvement. Bilateral uveitis was detected in two-thirds of patients with posterior chamber affected, and it tends to recur more (p=0.014). Conclusion A rheumatological disease was detected in approximately one-third of the patients presenting with uveitis. Investigation of patients referred for uveitis in terms of systemic rheumatological diseases is very important as it may change the diagnosis and treatment process. Disclosure of Interests None declared
AB0771 Evaluation of the efficacy of inhibitors of tumor necrosis factor alpha for patients with ankylosing spondylitis in real clinical practice.
Authors: E. Rozochkina, E. Koltsova, D. Murtazalieva, E. Zhilyaev, E. Koshkarova, G. Lukina
Journal: Annals of the Rheumatic Diseases (2022)

Background The question of the comparative efficacy of tumor necrosis factor-alpha (TNF-α) inhibitors is topical today, because the research data that were distributed in random sequence mainly reflect the efficacy of the only specific drug, and the available data obtained in the ankylosing spondylitis (AS) treatment use of a network meta-analysis are limited. Objectives To make a comparative evaluation of the efficacy of various TNF-α inhibitors for patients with AS in real clinical practice. Methods The study involved patients with a reliable diagnosis of AS (according to the 1984 New York criteria) who received TNF-α inhibitor during the 12-month course of therapy, from 2018 to 2022. The efficacy of the drugs was evaluated by the ASDAS (CRP) (Ankylosing Spondylitis Disease Activity Score) and BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) – disease activity indices obtained 6 and 12 months after the start of therapy. Comparison of indicators between drugs was carried out using a non-parametric Kruskal-Wallis test, designed to test the equality of the medians of several samples. Results The study involved 257 patients with AS who were treated with various TNF-α inhibitors, among which Adalimumab was taken by 77 patients (29.96%), Golimumab - 20 (7.78%), Infliximab - 15 (5.84%), Certolizumab pegol - 27 (10.51%) and Etanercept - 118 (45.91%). The mean age of the involved patients was 46.1 ± 11.4 years old, the mean age at the onset of the disease was 28.7 ± 11.7 years old. The majority of patients were males - 167 (64.98%), 143 (55.64%) had Higher education, 163 (63.42%) were married, 103 (40.08%) have been working and - 150 patients (58.37%) had never smoked before the study. Mean ASAS (CRP) and BASDAI, disease activity indices, values ​​for each drug before therapy, 6 and 12 months after the start of therapy are presented in Table 1. «Head-to-head» comparison of medical preparations revealed no significant differences between TNF-α inhibitors in terms of the studied parameters (p &gt; 0.05). Table 1. Months since start of therapy BASDAI ASDAS (CRP) Adalimumab 0 5,84 3,38 6 3,52 1,91 12 4,11 2,24 Golimumab 0 5,91 3,29 6 5,17 2,91 12 4,61 2,68 Infliximab 0 3,56 2,25 6 2,59 1,08 12 2,20 1,39 Certolizumab pegol 0 6,57 3,80 6 3,38 2,17 12 3,50 2,81 Etanercept 0 6,13 3,79 6 3,75 2,20 12 3,80 2,28 ASDAS - Ankylosing Spondylitis Disease Activity Score; BASDAI - Bath Ankylosing Spondylitis Disease Activity Index; CRP - C-reactive protein Conclusion The studied TNF-α inhibitors demonstrate similar clinical efficacy in real clinical practice. A direct comparison of drugs didn’t reveal significant differences between TNF-α inhibitors. Disclosure of Interests None declared
POS0396 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors: J. H. Jung, A. Kim, B. Y. Kim, G. G. Song
Journal: Annals of the Rheumatic Diseases (2022)

Background Characterizing differentially expressed genes (DEGs) of systemic lupus erythematosus (SLE) is necessary to understand immunogenic interactions, and how several key immune genes were closely associated with the susceptibility of SLE. Objectives This study aimed to identify DEGs of SLE using gene expression-based computational methodologies to analyze disease-immune interactions, which affect the development and progression of SLE. Methods Twenty-six patients with SLE and 46 healthy controls were selected from the Gene Expression Omnibus database. The significantly enriched immune and virus related gene lists were computed and visualized by using the DEGs from the Gene Set Enrichment Analysis. Quantification of 38 immune cells were performed in determining the impact of immune cells on the virus mediated immunity in SLE by using ImmQaunt algorithm. Results Thirty nine upregulated and 57 downregulated were identified in SLE patient compared to the healthy controls. Upregulated genes were significantly implicated in Gene Ontology gene sets as cytokine mediated signaling, secretion, and exocytosis in immune response pathways. In addition, these genes were enriched in hepatitis C, influenza A, measles, Epstein–Barr virus, and herpes simplex virus 1 infection in Kyoto Encyclopedia of Genes and Genomes pathways. Especially, FCGR1A, IRF7, OAS2, CAMP, MX1, OAS3, OAS1, DEFA3, ISG15, and RSAD2 were involved in virus mediated SLE mechanism, and the expression for OAS1, OAS2, and IRF7 was closely associated with the quantities of colony forming unit-monocyte and colony forming unit-granulocyte. Conclusion Identifying virus mediated SLE genes and quantifies of immune cells were used to understand the pathological process and perform early diagnosis of SLE, and will lead to clinical tools for treating SLEs in patients. References [1]Ghodke-Puranik Y and Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. J Autoimmun 2015; 64: 125-136. [2]Teruel M and Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned. J Autoimmun 2016; 74: 161-175. [3]Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013; 65: 447-456. [4]Frishberg A, Brodt A, Steuerman Y and Gat-Viks I. ImmQuant: a user-friendly tool for inferring immune cell-type composition from gene-expression data. Bioinformatics 2016; 32: 3842-3843. Disclosure of Interests None declared.
AB0793 Facet joint disease in patients with axial spondyloarthritis: a retrospective conventional computed tomography study
Authors: G. Slobodin, M. Sagiv, T. Khreish, A. Shouval, S. Croitoru, I. Eshed
Journal: Annals of the Rheumatic Diseases (2022)

Background Facet joints’ (FJ) ankylosis was reported to occur frequently in patients with ankylosing spondylitis (AS). However, a detailed FJ evaluation was not reported in patients over the spectrum of axial spondyloarthritis (AxSpA). Objectives To analyze structural lesions in the FJ of patients with different forms of AxSpA, using computed tomography (CT). Methods All available conventional CT studies of the cervical, thoracic, lumbar spine, or studies of the chest or abdomen of patients with AS or non-radiographic AxSpA (nrAxSpA) from a single medical center cohort were analyzed for the presence of erosions, ankylosis, joint-space narrowing, osteophytes, subchondral sclerosis, subchondral cysts and vacuum phenomenon by 2 experienced readers. All patients, as well as age and gender matched control group, who performed conventional CT of the spine for any cause, but did not have a known rheumatic disease, had to be at the age of 50 years or less at the time of the study. The findings were binarically scored as present/absent. Several types of changes could be noted in the same FJ. All FJ findings were compared between groups of AxSpA patients and controls, separately for the cervical, thoracic and lumbar spine. Further, AxSpA patients were subdivided into three groups of which FJ findings were compared: AS patients with (AS+) or without (AS-) syndesmophytes on the cervical or lumbar radiographs, and patients with nrAxSpA as per pelvic radiograph. Fisher’s exact test or Chi-Square test at &lt; http://vassarstats.net &gt;, were used to compare between groups. Results 959/666 FJs (49/44 patients) were assessed in the AxSpA/control group patients, respectively. The study group consisted of 16 AS+ patients, 22 AS- patients, and 11 nrAxSpA patients. FJ ankylosis was significantly more prevalent in all spinal segments of the AS + group compared to the two other groups. Erosions were seen almost exclusively in patients with AS. Joint-space narrowing and osteophytes were noted in all segments and all subgroups of AxSpA patients, including those with nrAxSpA. Conclusion FJ involvement is prevalent in all forms of AxSpA, including its non-radiographic form. Facet joints of all spinal segments are involved in AxSpA patients References [1]Jung JY, Kim MY, Hong YS, Park SH, Kang KY. Association between facet joint ankylosis and functional impairment in patients with radiographic axial spondyloarthritis. Seminars in arthritis and rheumatism. 2021; 51(5):1005-1010. [2]Stal R, van Gaalen F, Sepriano A, Braun J, Reijnierse M, van den Berg R, et al. Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. Rheumatology. 2020; 59(12):3776-3783. Disclosure of Interests None declared